Nigel Rice
Publications and Insights
- Publication: Altering the trajectory of HIV in Europe
- Insight: GLP-1 Receptor Agonists: Shifting Obesity Management
- Publication: An Analysis of NICE’s Optimised Decisions from 2015 to 2024
- Publication: Challenges and Solutions for Budget Impact Analysis of Gene Therapies
- Insight: Advancing Rare Disease Care: Challenges and Key Issues
- Insight: EQ-5D and beyond: OHE’s contributions to EuroQol research and meetings
- Insight: Infectious disease: another reason to try Veganuary for the NHS
- Publication: Understanding societal preferences for priority by disease severity in England & Wales
- Publication: How Have HTA Agencies Evolved Their Methods Over Time?
- Publication: Socio-Economic Value of Adult Immunisation Programmes
- Insight: Kahneman’s legacy in health economics
- Publication: Individual, Health System, and Societal Impacts of Anti-seizure Medicine Use During Pregnancy
- Insight: Navigating the Intersection of Healthcare and Environmental Sustainability: ISPOR Europe round-up on the inclusion of environmental impact in HTA
- Insight: Could Plant-based Diets Transform Health Care Spending?
- Publication: NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?
- Publication: Are Recommendations for HTA of Gene Therapies Being Achieved?
- Publication: The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society
- Insight: How Restrictive are NICE ‘Optimised’ Decisions?
- Publication: Delivering the Triple Win: A Value-Based Approach to Pricing
- Publication: Navigating the Landscape of Digital Health – United Kingdom
- Insight: ISPOR Europe Round-up: “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?”
- Insight: ISPOR Issue Panel Roundup: Are Our HTA Methods Fit for Purpose for Gene Therapies?
- Insight: NICE’s severity modifier: a step in the right direction, but still a long way to go
- Insight: The NICE Health Technology Evaluation Manual: A Fresh Perspective Needed?
- Insight: Including Carer Quality of Life in Health Technology Evaluation: Are We There Yet?
- Insight: Rare Disease Day 2022
- Publication: Supporting the Era of Green Pharmaceuticals in the UK
- Publication: Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?
- Publication: When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies
- Publication: Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
- Publication: A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases
- Publication: How is Quality of Life Measured for Health Technology Assessments?
- Publication: Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?
- Insight: A NICE Wind of Change? The What and So What of the NICE Methods Consultation
- New: Ethical and Economic Issues in the Appraisal of Medicines for Ultra-rare (or Ultra-orphan) Conditions
- Publication: The BRAVE Initiative: The BRAVE Narrative for Broad Recognition of Value in Vaccines Engagement
- Publication: Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
- Publication: Ethical and Economic Issues in the Appraisal of Medicines for Ultra-Rare Conditions